Published in Front Oncol on December 03, 2013
The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol (2014) 1.43
The biology and treatment of oligometastatic cancer. Oncotarget (2015) 1.08
SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer. Front Oncol (2015) 0.80
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (2000) 5.03
Oligometastases. J Clin Oncol (1995) 4.95
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys (2010) 3.87
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer (1988) 2.96
Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol (2007) 2.80
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.57
Oligometastases revisited. Nat Rev Clin Oncol (2011) 2.42
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol (2013) 2.26
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol (2005) 2.18
Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol (2013) 2.16
Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res (1997) 2.16
Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013) 2.15
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol (1999) 2.03
Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys (2011) 2.03
Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer (2011) 1.98
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol (2012) 1.90
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol (2002) 1.77
Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys (2013) 1.77
Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.73
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol (2009) 1.72
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2011) 1.70
Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol (2004) 1.66
Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.61
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys (1991) 1.58
Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol (2009) 1.51
Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol (2013) 1.48
MicroRNA expression characterizes oligometastasis(es). PLoS One (2011) 1.45
Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol (2008) 1.41
Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol (1995) 1.31
Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol (2011) 1.31
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer (2011) 1.28
Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist (2012) 1.25
Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol (2008) 1.24
Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol (2003) 1.21
Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med (2007) 1.19
Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol (2004) 1.17
Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys (2004) 1.17
Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol (2013) 1.12
Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer (2012) 1.11
Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer (1993) 1.08
Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiother Oncol (2009) 1.05
Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol (2013) 1.01
New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol (2011) 1.01
Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol (1993) 1.00
Health-related quality of life among patients with metastatic prostate cancer. Urology (1997) 0.96
Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys (1998) 0.93
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91
Stereotactic body radiotherapy in the management of painful bone metastases. Oncology (Williston Park) (2008) 0.87
Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol (2012) 0.84
Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol (2012) 0.80
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys (2011) 0.76
Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer. Front Oncol (2014) 0.84
Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer. Front Oncol (2014) 0.82
Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design? Front Oncol (2015) 0.77
Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer. Front Oncol (2015) 0.77
Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging. Front Oncol (2015) 0.76
Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience. Front Oncol (2016) 0.76
Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity. Front Oncol (2017) 0.75
Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design. Front Oncol (2016) 0.75